Activist Investor Demands Exelixis Cut R&D Spending And Learn From Peers

CEO Pushes Back On R&D Spending Cut Calls

 
• By Andrew McConaghie

The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.

Stock Index close up
The activist investors insist that greater focus on R&D spending and shareholder return will be good for business

More from Anticancer

More from Therapy Areas